Cargando…
Metabolic and hemodynamic effects of sodium‐dependent glucose cotransporter 2 inhibitors on cardio‐renal protection in the treatment of patients with type 2 diabetes mellitus
The specific sodium–glucose cotransporter 2 inhibitors (SGLT2 inhibitors) inhibit glucose reabsorption in proximal renal tubular cells, and both fasting and postprandial glucose significantly decrease because of urinary glucose loss. As a result, pancreatic β‐cell function and peripheral insulin act...
Autores principales: | Kashiwagi, Atsunori, Maegawa, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497037/ https://www.ncbi.nlm.nih.gov/pubmed/28178390 http://dx.doi.org/10.1111/jdi.12644 |
Ejemplares similares
-
Sodium–glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients
por: Kashiwagi, Atsunori, et al.
Publicado: (2020) -
Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017) -
Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
por: Kim, Nam Hoon, et al.
Publicado: (2022) -
Randomized, placebo‐controlled, double‐blind glycemic control trial of novel sodium‐dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus
por: Kashiwagi, Atsunori, et al.
Publicado: (2013) -
A new era of diabetic kidney disease treatment with sodium–glucose cotransporter‐2 inhibitors
por: Kume, Shinji, et al.
Publicado: (2022)